Clack has more than 30 years’ experience in oncology and translational medicine and held various roles within AstraZeneca for almost 20 years.
He specialised in early phase oncology clinical development with an emphasis on a number of cancers and has experience conducting and managing clinical trials. He successfully provided strategic and operational leadership from Phase I through to regulatory submissions and commercialisation.
He has been a lead member of study, clinical development and project teams on multiple trials.
“We are delighted to have someone of Glen’s experience and knowledge join our team,” said Dr Huw Jones, chief executive of Evgen.
“As we progress further with our clinical programmes, Glen’s depth of understanding in the fields where we are active will be invaluable. Glen will also be a key member of the team involved in leveraging our relationships with our many partners. His unique skillset has seen him take responsibility for a number of large, complex projects and he has published over 50 academic papers on various cancers.”